The new site is for people in the U.S. who are willing to pay out of pocket for certain brand-name medications, like Zepbound ...
Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months. In large part, that rebound was fueled ...
The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...
Eli Lilly's full-year guidance comes in stark contrast to the outlook of Novo Nordisk, which warned it sees sales and profit ...
With just a few months to go before Eli Lilly expects to launch its own oral GLP-1 obesity drug, Novo Nordisk is making the ...